A detailed history of Voya Investment Management LLC transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Voya Investment Management LLC holds 48,517 shares of ABUS stock, worth $154,769. This represents 0.0% of its overall portfolio holdings.

Number of Shares
48,517
Previous 49,266 1.52%
Holding current value
$154,769
Previous $152,000 22.37%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.12 - $4.56 $2,336 - $3,415
-749 Reduced 1.52%
48,517 $186,000
Q2 2024

Dec 03, 2024

BUY
$2.52 - $3.63 $1,887 - $2,718
749 Added 1.54%
49,266 $152,000
Q2 2024

Aug 14, 2024

BUY
$2.52 - $3.63 $10,989 - $15,830
4,361 Added 9.71%
49,266 $152,000
Q1 2024

Dec 06, 2024

SELL
$2.26 - $2.92 $8,163 - $10,547
-3,612 Reduced 7.44%
44,905 $115,000
Q1 2024

May 15, 2024

SELL
$2.26 - $2.92 $25,736 - $33,252
-11,388 Reduced 20.23%
44,905 $115,000
Q4 2023

Feb 14, 2024

SELL
$1.69 - $2.54 $139,725 - $210,002
-82,678 Reduced 59.49%
56,293 $140,000
Q3 2023

Nov 14, 2023

BUY
$1.9 - $2.27 $25,156 - $30,054
13,240 Added 10.53%
138,971 $282,000
Q2 2023

Aug 14, 2023

BUY
$2.24 - $3.06 $187,091 - $255,580
83,523 Added 197.88%
125,731 $289,000
Q2 2022

Aug 15, 2022

BUY
$1.98 - $3.17 $22,316 - $35,729
11,271 Added 36.43%
42,208 $114,000
Q4 2021

Feb 14, 2022

SELL
$3.11 - $4.61 $2,814 - $4,172
-905 Reduced 2.84%
30,937 $120,000
Q2 2021

Aug 16, 2021

BUY
$2.5 - $3.51 $79,605 - $111,765
31,842 New
31,842 $96,000
Q2 2019

Aug 14, 2019

SELL
$1.46 - $4.44 $19,569 - $59,513
-13,404 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$5.0 - $7.35 $67,020 - $98,519
13,404 New
13,404 $98,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $478M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Voya Investment Management LLC Portfolio

Follow Voya Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.